RhumbLine Advisers
NRIX icon

RhumbLine Advisers’s Nurix Therapeutics NRIX Stock Holding History

RhumbLine Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99M Sell
123,072
-295
-0.2% -$5.03K ﹤0.01% 1737
2026
Q1 		$1.91M Buy
123,367
+4,769
+4% +$79.1K ﹤0.01% 1883
2025
Q4 		$2.25M Buy
118,598
+4,180
+4% +$60K ﹤0.01% 1814
2025
Q3 		$1.06M Sell
114,418
-10,809
-9% -$112K ﹤0.01% 2214
2025
Q2 		$1.43M Buy
125,227
+14,739
+13% +$159K ﹤0.01% 2067
2025
Q1 		$1.31M Buy
110,488
+7,255
+7% +$121K ﹤0.01% 2042
2024
Q4 		$1.94M Buy
103,233
+12,315
+14% +$282K ﹤0.01% 1892
2024
Q3 		$2.04M Buy
90,918
+2,137
+2% +$48.4K ﹤0.01% 1901
2024
Q2 		$1.85M Buy
88,781
+11,010
+14% +$171K ﹤0.01% 1924
2024
Q1 		$1.14M Buy
77,771
+2,664
+4% +$28.7K ﹤0.01% 2181
2023
Q4 		$775K Buy
75,107
+58
+0.1% +$398 ﹤0.01% 2403
2023
Q3 		$590K Buy
75,049
+1,993
+3% +$18.2K ﹤0.01% 2515
2023
Q2 		$730K Buy
73,056
+244
+0.3% +$2.49K ﹤0.01% 2463
2023
Q1 		$647K Buy
72,812
+2,045
+3% +$21.3K ﹤0.01% 2317
2022
Q4 		$777K Buy
70,767
+677
+1% +$8.16K ﹤0.01% 2262
2022
Q3 		$913K Buy
70,090
+7,051
+11% +$112K ﹤0.01% 2177
2022
Q2 		$799K Buy
63,039
+29,528
+88% +$335K ﹤0.01% 2248
2022
Q1 		$469K Buy
33,511
+1,573
+5% +$27.9K ﹤0.01% 2448
2021
Q4 		$925K Buy
31,938
+864
+3% +$26.2K ﹤0.01% 2244
2021
Q3 		$931K Buy
31,074
+1,258
+4% +$38.8K ﹤0.01% 2251
2021
Q2 		$791K Buy
29,816
+5,601
+23% +$164K ﹤0.01% 2347
2021
Q1 		$753K Buy
24,215
+12,592
+108% +$476K ﹤0.01% 2312
2020
Q4 		$382K Buy
11,623
+2,110
+22% +$69.9K ﹤0.01% 2557
2020
Q3 		$332K Buy
+9,513
New +$240K ﹤0.01% 2467

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's NRIX Position: Q2 2026 in Review

RhumbLine Advisers reduced its Nurix Therapeutics (NRIX) stake by 0.24% in Q2 2026, selling an estimated $5.03K and leaving 123,072 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1737.

RhumbLine Advisers first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • RhumbLine Advisers held 123,072 shares of Nurix Therapeutics worth $2.99M as of Q2 2026.
  • RhumbLine Advisers sold 295 Nurix Therapeutics shares in Q2 2026, an estimated $5.03K.
  • Nurix Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1737 holding.
  • RhumbLine Advisers first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.